Democratic candidates take the stage together for the first time as they jockey for position in the race to take on President Trump in 2020.2020 Electionsread more
The issue over health insurance marked the first stark divide among the candidates, and sparked a heated back-and-forth between many of the candidates on stage.Politicsread more
In a strategy to draw attention away from Wednesday's Democratic debate, President Donald Trump's reelection campaign bought out YouTube's "masthead," the leading...2020 Electionsread more
Virginia Sen. Mark Warner breaks down the idea behind a bipartisan bill he introduced to provide more transparency in Big Tech.Technologyread more
The Federal Aviation Administration said on Wednesday that is has found an issue with the Boeing 737 Max that the manufacturer must address before it lifts the grounding...Airlinesread more
Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
These attacks have given the public the opportunity to examine the problems associated with ransomware, where corporations -- not obligated to disclose these attacks -- have...Technologyread more
"As a private company we don't have the tools to make the Russian government stop," Facebook CEO Mark Zuckerberg said at the Aspen Ideas Conference on Wednesday. "We can...Technologyread more
Something unusual is happening in financial markets, and it could mean more gains lie ahead for stocks, if history is any indication.Marketsread more
Underneath the impressive market rally is a trend that doesn't seem quite right, according to J.P. Morgan.Marketsread more
Wi-Fi 6 will be the next-generation wireless standard. Along with 5G, it will represent the next big shift in connectivity and data, said Irving Tan, senior vice president and...Shaping the futureread more
Pfizer on Tuesday beat the Street's fourth-quarter earnings expectations and laid out its plans for the new tax law.
The pharmaceutical giant reported adjusted earnings per share of 62 cents. The Street had expected earnings per share of 56 cents. Revenue on $13.7 billion was in line with expectations.
Pfizer's innovative health unit grew 5 percent on an operational basis from a year earlier, reaching $8.2 billion in revenue driven by Eliquis, Xeljanz and Prevenar. Its essential health business decreased 8 percent operationally year over year, falling to $5.4 billion.
Here's how Pfizer did compared with what Wall Street expected:
In the fourth quarter, the company reported a net profit of $12.3 billion, or $2.02 per share. However, after stripping out special items, the company earned $3.8 billion, or 62 cents per share, in the latest period, outpacing analyst estimates of 56 cents per share.
For the full year, Pfizer forecasts revenue ranging $53.5 billion to $55.5 billion and adjusted earnings per share ranging $2.90 to $3, above the Street's estimates of $53.9 billion and $2.78 per share, respectively. The guidance includes $5 billion in buybacks.
Pfizer said its effective tax rate on adjusted income will be about 17 percent next year, down from 20 percent this year. It anticipates a $15 billion tax bill over eight years to repatriate its overseas cash.
In wake of the new tax law, the company plans to invest approximately $5 billion in capital projects in the U.S., including building its manufacturing presence. It plans to contribute $500 million to its U.S. pension plan and has allocated about $100 million for a special, one-time bonus for all nonexecutive employees in the first quarter of 2018.
Pfizer also contributed $200 million to the Pfizer Foundation.
Bids are due Thursday for its consumer health unit. The company expects the business, which includes brands like Advil and ChapStick, to generate about $20 billion. Johnson & Johnson dropped out of the competition, leaving GlaxoSmithKline and Reckitt Benckiser among those preparing bids.
"We remain on track to make this decision, which could include everything from a full or partial separation to ultimately deciding to retain the business, during 2018," CEO Ian Read said in a statement.